- ISIN
- US67080N1019
- CUSIP
- 67080N101
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Aug 24, 2020
Highlights
- Market Cap
- $2.20B
- Enterprise Value
- $2.09B
- EPS (TTM)
- -$0.41
- Total Revenue (TTM)
- $143.05M
- Gross Profit (TTM)
- $131.08M
- EBITDA (TTM)
- -$139.03M
- Year Range
- $2.18 - $9.75
- Target Price
- $12.40
- ROA (TTM)
- -23.92%
- ROE (TTM)
- -45.69%
- Avg. Volume (1M)
- 6M
- Avg. Volume Value (1M)
- $39.41M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NUVB Performance Chart
Nuvation Bio Inc. (NUVB) is down 29.4% since the beginning of the year. At $6 per share, NUVB is trading 35.1% below its 52-week high of $10. Investors who bought $1,000 worth of NUVB shares 5 years ago would now be looking at an investment worth $733.
Loading charts...
Compare this symbol against anything
Returns By Period
Nuvation Bio Inc. (NUVB) has returned -29.35% so far this year and 183.86% over the past 12 months.
Nuvation Bio Inc.
- 1D
- -5.52%
- 1M
- 11.05%
- 6M
- 20.80%
- YTD
- -29.35%
- 1Y
- 183.86%
- 3Y*
- 49.62%
- 5Y*
- -6.03%
- 10Y*
- —
- ALL TIME*
- -7.42%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
NUVB Monthly Returns History
Based on dividend-adjusted daily data since Aug 24, 2020, NUVB's average daily return is +0.07%, while the average monthly return is +1.46%. At this rate, an investment would double in approximately 4.0 years.
Historically, 47% of months were positive and 53% were negative. The best month was Mar 2024 with a return of +94.7%, while the worst month was Jan 2026 at -41.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.
On a daily basis, NUVB closed higher 46% of trading days. The best single day was Nov 19, 2025 with a return of +49.0%, while the worst single day was Mar 3, 2026 at -25.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -41.52% | 12.79% | -27.41% | 3.73% | 7.42% | 18.83% | 11.44% | -29.35% | |||||
| 2025 | -13.16% | -14.72% | -10.66% | 27.84% | -5.78% | -8.02% | 21.03% | 25.85% | 24.58% | 41.08% | 53.83% | 11.58% | 236.84% |
| 2024 | 7.28% | 15.43% | 94.65% | -17.86% | 3.68% | -5.81% | 31.16% | -15.93% | -28.88% | -3.49% | 31.22% | -8.28% | 76.16% |
| 2023 | 28.13% | -21.14% | -14.43% | -3.01% | 0.62% | 11.11% | 2.78% | -11.35% | -18.29% | -28.09% | 28.68% | 21.77% | -21.35% |
| 2022 | -28.24% | -17.05% | 3.95% | -11.41% | -24.25% | -8.22% | -14.81% | 1.45% | -20.00% | -1.79% | -13.18% | 0.52% | -77.41% |
| 2021 | -12.39% | -2.15% | 4.19% | 7.08% | 27.08% | -34.53% | -7.20% | 6.83% | 7.69% | -7.75% | -2.18% | -5.24% | -27.35% |
Benchmark Metrics
Nuvation Bio Inc. has an annualized alpha of -0.66%, beta of 1.26, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since August 24, 2020.
- This stock participated in 172.86% of S&P 500 Index downside but only 89.01% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -0.66%
- Beta
- 1.26
- R²
- 0.08
- Upside Capture
- 89.01%
- Downside Capture
- 172.86%
Return for Risk
Risk / Return Rank
NUVB ranks 87 for risk / return — above 87% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Nuvation Bio Inc. (NUVB) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NUVB | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.51 | ||
| Sortino ratioReturn per unit of downside risk | +0.72 | ||
| Omega ratioGain probability vs. loss probability | 1.37 | 1.25 | +0.11 |
| Calmar ratioReturn relative to maximum drawdown | 2.94 | 2.00 | +0.94 |
| Martin ratioReturn relative to average drawdown | 4.90 | 8.49 | -3.59 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Nuvation Bio Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Nuvation Bio Inc. was 93.39%, occurring on Oct 31, 2023. The portfolio has not yet recovered.
The current Nuvation Bio Inc. drawdown is 56.55%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-93.39%Oct 2023 | 2y 7mo | — | 5y 4moMar 2021 - now | — |
-23.73%Feb 2021 | 1mo 7d | 25d | 2mo 2dJan 2021 - Mar 2021 | — |
-13.87%Dec 2020 | 2mo 17d | 29d | 3mo 16dSep 2020 - Dec 2020 | — |
-5.16%Sep 2020 | 2d | 6d | 8dSep 2020 - Sep 2020 | — |
-4.27%Jan 2021 | 1d | 1d | 1dJan 2021 - Jan 2021 | — |
Drawdown Indicators
| NUVB | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.39% | -56.78% | -36.61% |
Max Drawdown (1Y)Largest decline over 1 year | -57.55% | -9.10% | -48.45% |
Max Drawdown (3Y)Largest decline over 3 years | -58.19% | -18.90% | -39.29% |
Max Drawdown (5Y)Largest decline over 5 years | -90.41% | -25.43% | -64.98% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -56.55% | -1.58% | -54.97% |
Average DrawdownAverage peak-to-trough decline | -65.32% | -10.70% | -54.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 34.48% | 2.14% | +32.34% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Nuvation Bio Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Nuvation Bio Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for NUVB relative to other companies in the Biotechnology industry. Currently, NUVB has a P/S ratio of 15.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NUVB in comparison with other companies in the Biotechnology industry. Currently, NUVB has a P/B value of 7.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NUVB
Add Nuvation Bio Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NUVB